
|Articles|October 1, 2001
Verteporfin for injection
The FDA has approved Visudyne (verteporfinfor injection) therapy for the treatment of predominantly classic subfovealchoroidal neovascularization (CNV) caused by pathologic myopia and presumedocular histoplasmosis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
3
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
4
Eye exams could enable earlier detection of systemic disease
5



























